Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681182 · ClinicalTrials.gov registry record · Phase 4
Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone
A Phase 4 study, sponsored by WakeMed Health and Hospitals.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT05681182: Completed Phase 4 study, sponsored by WakeMed Health and Hospitals.
NCT05681182 is a Phase 4 study that has completed, run by WakeMed Health and Hospitals. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05681182, a Phase 4 study, has completed, sponsored by WakeMed Health and Hospitals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing isolated cardiac arterial bypass grafting (CABG) or valve surgery.
Primary Outcome
The patient have continuous ECG monitoring until discharge to evaluate for any evidence of atrial fibrillation or atrial flutter which lasts longer than one hour or if less than one hour, requires medical or procedural intervention
Interventions
- COMBINATION_PRODUCT CardiaMend with the Addition of Amiodarone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 4 |
What the finished NCT05681182 record still lists
NCT05681182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which CardiaMend with the Addition of Amiodarone is the first listed.
NCT05681182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05681182 about?
NCT05681182 is a clinical study titled "Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone". The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing isolated cardiac arterial bypass grafting (CABG) or valve surgery.
What is the current status of trial NCT05681182?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-01-20. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT05681182?
The interventions under investigation include: CardiaMend with the Addition of Amiodarone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05681182?
This trial is sponsored by WakeMed Health and Hospitals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05681182's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI